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Abstract
Two ATP-binding cassette (ABC) proteins, ABCG5 and ABCG8, have recently been associated with the accumulation of dietary
cholesterol in the sterol storage disease sitosterolemia. These two ‘half-transporters’ are assumed to dimerize to form the complete sitosterol
transporter which reduces the absorption of sitosterol and related molecules in the intestine by pumping them back into the lumen. Although
mutations altering ABCG5 and ABCG8 are found in affected patients, no functional demonstration of sitosterol transport has been achieved.
In this study, we investigated whether other ABC transporters implicated in lipid movement and expressed in tissues with a role in sterol
synthesis and absorption, might also be involved in sitosterol transport. Transport by the multidrug resistance P-glycoprotein (P-gp; Abcb1),
the multidrug resistance-associated protein (Mrp1; Abcc1), the breast cancer resistance protein (Bcrp; Abcg2) and the bile salt export pump
(Bsep; Abcb11) was assessed using several assays. Unexpectedly, none of the candidate proteins mediated significant sitosterol transport.
This has implications for the pathology of sitosterolemia. In addition, the data suggest that otherwise broad-specific ABC transporters have
acquired specificity to exclude sitosterol and related sterols like cholesterol presumably because the abundance of cholesterol in the
membrane would interfere with their action; in consequence, specific transporters have evolved to handle these sterols.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Sitosterolemia is a rare, autosomal recessive sterol stor-
age disease characterised by tendon and tuberous xanthomas
and by a strong predisposition to premature coronary
atherosclerosis [1,2]. Increased levels of phytosterols (plant
sterols) such as sitosterol and campesterol are found in
blood, plasma, erythrocytes and especially in xanthomas
and arteries of affected subjects. Increased intestinal absorp-
tion of phytosterols as well as decreased biliary and fecal
excretion of cholesterol and phytosterols contribute to the
abnormal lipid composition of blood and tissues from these
patients. These phenotypes could be a consequence of either
increased absorption or of decreased efflux of sterols.
Many adenosine triphosphate (ATP)-binding cassette
(ABC) transporters mediate efflux of hydrophobic mole-
cules from cells. Recently, mutations in two divergent
genes encoding ABC transporters have been associated
with sitosterolemia [3–5]. The ‘half-transporters’, ABCG5
and ABCG8, encoded by these genes are highly expressed
in liver and intestine and presumably act together to form a
complete transporter. It is assumed, but has not been
demonstrated, that these transporters mediate sitosterol
efflux and, when inactive, sitosterol accumulation is
increased. Cholesterol feeding up-regulates their expression
in mice, implicating them in the intestinal absorption and
biliary excretion of sterols [3]. However, little is yet known
about the transport of sterols across cell membranes. Since
several ABC transporters have been implicated in lipid,
phospholipid and cholesterol transport, it seemed likely that
other members of the ABC transporter family may also
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play a role in pumping sitosterol in and other sterols out of
cells.
The multidrug resistance P-glycoprotein (P-gp, also des-
ignated as ABCB1, encoded by the MDR1 gene) transports
a wide variety of hydrophobic compounds, including ste-
roids, out of cells in a manner analogous to phospholipid
flippases which maintain phospholipid asymmetry between
leaflets of the lipid bilayer [6]. P-gp is known to transport
analogues of membrane lipids with shortened acyl chains
[7,8]. It has been suggested that P-gp may have a physio-
logical role in the transport of natural membrane lipids
including cholesterol [9–13], although this is still a matter
of debate. The closely related MDR3 (also designated as
ABCB4) gene product is known to flip phosphatidyl choline
across the canalicular membrane during bile formation [14–
16]. The multidrug resistance-associated protein (Mrp1 also
designated as ABCC1) also transports various lipid ana-
logues (reviewed in Refs. [17,18]). Other ABC transporters
involved in lipid transport include ABCR (also called rim
protein or ABCA4), which transports a complex of retinal-
dehyde and phosphatidylethanolamine in the retina of the
eye [19]; ABCA1 which is crucial for the elimination of
excess tissue cholesterol (reviewed in Ref. [20]); ABCA6
which is potentially involved in lipid homeostasis [21];
peroxisomal ABC transporters which are involved in the
import of long-chain fatty acids into peroxisomes [22,23]
and ABCG1, the human homolog of the Drosophila white
gene, which is implicated in the regulation of macrophage
cholesterol and phospholipid transport [24,25].
The bile salt export pump (Bsep, also designated as
Abcb11), is regarded as the key mediator of canalicular bile
salt excretion. Bsep is known to affect the homeostasis of
cholesterol and phospholipids. Thus, secretion of phospho-
lipids and cholesterol usually correlates positively with the
secretion of bile salts in vivo [26], and it is widely accepted
that bile salt secretion drives the secretion of phospholipids
and cholesterol into the bile. Disruption of the Bsep gene in
mice also significantly increases biliary cholesterol and
phospholipids [27]. Interestingly, the Bsep locus maps to
2q24, co-localises with the Lith1 locus of cholesterol gall-
stone susceptibility in mice [28], and is located in the
proximity of the sitosterolemia locus which has been map-
ped to human chromosome 2p21 [29].
To date, no functional measurements of sitosterol trans-
port by different ABC transporters have been reported. As
many ABC transporters play crucial roles in lipid transport,
we studied ABC transporter proteins known to be expressed
in cell membranes of tissues with a potential role in sitosterol
transport. P-gp is highly expressed in the canalicular mem-
brane of the liver and the gut epithelium [30]; the breast
cancer resistance protein (Bcrp; also known as mitoxantrone
resistance-associated protein MXR, designated as ABCG2
according to the HUGO nomenclature) mRNA is found in
the small intestine, colon and liver as well as other tissues
[31]. Mrp1 is ubiquitously expressed [17] and is located on
the basolateral membrane of polarised cells [32]; Bsep is
expressed exclusively in the liver and has been localised by
immunohistochemistry to the canalicular membrane of hep-
atocytes [27,33,34]. The functional data obtained in this
study show that P-gp, Mrp1, Abcg2 and Bsep are unlikely to
be involved in sitosterol transport. These findings comple-
ment previous studies of sitosterolemic patients and give
new insights into the substrate specificity and physiological
role of individual ABC transporters.
2. Materials and methods
2.1. Mice
Mdr1a/b / mice were initially purchased from Taconic
Farms (Germantown, USA). Mdr1a and1b mutations had
been backcrossed for at least seven generations onto the FVB
background at Taconic Farms. FVB, FVB.mdr1a/b / and
C57BL/10 mice were bred in the Biological Services Unit at
the MRC Clinical Sciences Centre. Mice were used at 5 to 12
weeks of age.
2.2. Cell culture
NIH3T3 murine fibroblasts which had been permanently
transfected with the humanMDR1 gene, have been described
previously [35,36]. Parental NIH3T3 cells and MDR1-over-
expressing NIH3T3 fibroblasts (NIH3T3-MDR1) were cul-
tured in Dulbecco’s Modified Eagle’s medium (DMEM,
Gibco Life Technologies) supplemented with 10% fetal calf
serum (FCS). NIH3T3-MDR1 cells were maintained in
media supplemented with 1 Ag/ml colchicine (Sigma) to
ensure P-gp expression. Colchicine was withdrawn from the
medium 24 h prior to carrying out transport studies.
2.3. Calcein-AM assay for P-gp activity in NIH3T3 cells
2.3.1. Confocal microscopy
Calcein fluorescence in individual cells was measured by
epifluorescence confocal microscopy as described previously
[37], using a BioRad ARadiance microscope mounted on a
Zeiss Axiovert 100 and a 40 plan neofluor 1.3 NA oil
immersion objective. The experiments were performed with
an excitation line of 488 nm; the emitted light was collected
through a HQ500LP filter. Briefly, NIH3T3 cells were plated
at low density 48 h before the experiment on poly-L-lysine
coated cover slips and maintained in DMEM containing 10%
FCS with (NIH3T3-MDR1) or without (NIH3T3) 1 Ag/ml
colchicine. Colchicine was removed 24 h prior to the assays.
Experiments were performed with a isotonic perfusion sol-
ution (IPS) containing 140 mM NaCl, 2 mM CaCl2, 0.5 mM
MgCl2, 10 mM HEPES, 5 mM KCl and 1 g/l D-glucose, pH
7.3. Fluorescence changes were detected as a function of time
by collecting sequential images, usually at 20 s intervals, after
adding calcein-acetoxymethylester (AM; 2.5 AM, Molecular
Probes). Accumulation of calcein, measured by fluorescence
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increase, is inversely related to the rate of transport of P-gp
and was calculated as described previously [37]. h-sitosterol
was tested in final concentrations of 2–100 AM.
2.3.2. Flow cytometry
Cells were washed with phosphate buffered saline and
incubated at room temperature for 10 min with IPS contain-
ing 0.1 AM calcein-AM and one of the following compo-
nents: 20 AM cyclosporin A (CsA; Sigma), an inhibitor of P-
gp; 2–22 AM vinblastine (Sigma), a substrate for P-gp; 90
AM methotrexate (Sigma), which is not transported by P-gp;
2–100 AM h-sitosterol or 100 AM cholesterol. Ethanol
(0.1%) served as a diluent control. Cells were washed once
with IPS, detached with Trypsin-EDTA and centrifuged for 5
min at 400 g. The cell pellet was resuspended in 500 Al IPS
and fluorochrome efflux was assessed by flow cytometry.
Live cells were gated by eye on the basis of forward scatter
and side scatter characteristics and analysed using CellQuest
software (Beckton Dickinson).
2.4. ATPase assay for P-gp
P-gp-associated ATPase activity was determined accord-
ing to Litman et al. [38], by quantitating the release of
inorganic phosphate from ATP, using a sensitive, colorimet-
ric assay originally described by Chifflet et al. [39] and later
modified by Doige et al. [40]. Human P-gp containing Sf9
microsomes (K228, BD GenTest) were thawed on ice before
resuspension in ice-cold ATPase assay medium (3 mM ATP,
50 mM KCl, 2.5 mM MgSO4; 3 mM dithiothreitol, 25 mM
Tris–HCl, pH 7.0) containing 0.5 mM EGTA (to inhibit Ca-
ATPases), 2 mM ouabain (to inhibit the (Na +K)-ATPase),
and 3 mM azide (to inhibit mitochondrial ATPase). Each
series of experiments was carried out in a 96-well microtiter
plate, with reaction volumes of 50 Al/well corresponding to
5 Ag protein/well. Incubation with verapamil, a known
activator of the P-gp ATPase, and with h-sitosterol at
various concentrations was started by transferring the plate
from ice to 37 jC for 1 h, and terminated by the addition of
Fig. 1. Effect of sitosterol on P-gp activity in NIH3T3-MDR1 cells. Murine NIH3T3 cells permanently transfected with human MDR1 cDNA (NIH3T3-
MDR1) were incubated with 0.1 AM calcein-AM for 10 min and fluorochrome accumulation was measured in the absence of an inhibitor or substrate (A and B,
black lines), or in the presence of 20 AM cyclosporin A (CsA; panel A1, red), 100 AM h-sitosterol (panel A2, red), 100 AM cholesterol (panel A3, red), 90 AM
methotrexate (panel A4, red), or different concentrations of vinblastine (VBL; panels B1–3, red), respectively. Cells were analysed by flow cytometry. As
expected, CsA and VBL increased fluorescence (shifted curves to the right), demonstrating inhibition of P-gp activity, while sitosterol, cholesterol and
methotrexate had no effect. Numbers listed in panel B indicate mean fluorescence values of the gated cell population.
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200 Al ice-cold stopping medium (ammonium molybdate,
0.2% (w/v); sulfuric acid, 1.3% (v/v); SDS, 0.9% (w/v);
trichloroacetic acid, 2.3% (w/v); freshly prepared ascorbic
acid, 1% (w/v)) to each well. After 30 min incubation at
room temperature, the released phosphate was quantitated
colorimetrically using a microplate reader (Bio-Tek Instru-
ments) at 750 nm. Background and control experiments
with ATPase assay buffer alone, samples incubated on ice,
and samples incubated with 500 AM vanadate (inhibiting the
P-gp ATPase) were obtained in parallel and subtracted from
the measurements.
2.5. Analysis of P-gp, Mrp1 and Abcg2 activity by flow
cytometry in murine lymphocytes
Murine lymphocytes (107/ml) were incubated in the
presence of fluorochrome for 30 min at 37 jC in DMEM
(Sigma) supplemented with 1% bovine serum albumin
(BSA; Sigma), in the presence or absence of 2–100 AM h-
sitosterol (Sigma) or the following inhibitors: 20 AMCsA, an
inhibitor of P-gp; 70 AMMK571 (gift from Dr. B. Sarkadi), a
specific inhibitor of Mrp1; or 10 AM fumitremorgin C (gift
from Dr. S. Bates), a specific inhibitor of Abcg2. 0.1%
ethanol served as a diluent control. In order to discriminate
different lymphocyte populations, CD4QUANTUM RED or
CD8PE antibodies (Beckton Dickinson) were added for the
final 10 min of the incubation. Cells were washed once with
DMEM/BSA, resuspended in 200 Al DMEM/BSA and
fluorochrome efflux was assessed by flow cytometry. Live
cells were gated by eye on the basis of forward scatter and
side scatter characteristics and analysed using CellQuest
software (Beckton Dickinson). The following fluorochromes
were used: BODIPY-taxol (Molecular Probes) for P-gp;
0.025 AM Fluo-4 AM (Molecular Probes) or 0.0125 AM
Fig. 2. Effect of sitosterol on rate of transport by P-gp. Calcein accumulation by individual NIH3T3-MDR1 cells was measured by epifluorescence confocal
microscopy. (Panel A) Fluorescence intensity, shown color-coded on a scale from blue (low) to white (high), is proportional to the concentration of accumulated
calcein and inversely related to P-gp activity. Images of individual cells loaded with 2.5 AM calcein-AM are shown in the absence of h-sitosterol (left panel), in
the presence of 100 AM h-sitosterol (middle panel), and in the presence of 50 AM verapamil (right panel) 2 min after application of h-sitosterol and verapamil,
respectively. (Panel B) Quantitative analysis for several individual cells was performed measuring the average fluorescence intensity from an area within each
cell as a function of time (for clarity, the analysis of only two cells is shown). Sitosterol or verapamil were added where indicated by horizontal bars.
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calcein-AM for Mrp1; 0.5 AM mitoxantrone (Sigma) for
Abcg2.
2.6. Transport by Bsep in Sf9 insect cells
ATP-dependent bile acid uptake into Sf9 cell vesicles
expressing rat Bsep was performed as described previously
[34,41]. Briefly, Sf9 cells were infected with Bsep express-
ing baculovirus generated with the Bac-to-Bac system (Life
Technologies). The total membrane fraction was isolated
and vesicles resuspended in taurocholate uptake buffer
consisting of 50 mM sucrose, 100 mM KNO3 and 10 mM
HEPES/Tris, pH 7.4. Expression of Bsep in membrane
vesicles was demonstrated by Western blotting. Uptake of
2 AM [3H]-taurocholate (NEN Life Science Products) was
performed in the buffer system by rapid filtration technique
[42] in the absence or presence of 1–10 AM h-sitosterol; 1%
BSA was added to increase the solubility of h-sitosterol. A
potential inhibitory effect of h-sitosterol on ATP-dependent,
Bsep-mediated taurocholate transport in Sf9 vesicles was
investigated at initial (45 s), intermediate (5 min) and long
(2 h) periods of incubation with h-sitosterol; experiments
were performed in triplicate. ATP-dependent uptake was
calculated as the difference in uptake in the presence and
absence of ATP.
3. Results
To assess the transport of sitosterol by the different
ABC transporters, a variety of assays and the use of
different cell types expressing the various transporters were
required.
3.1. Sitosterol is not a substrate for P-gp
To study whether sitosterol interacts with P-gp, we first
assayed its ability to inhibit, competitively, P-gp-mediated
transport in NIH3T3 cells overexpressing P-gp (NIH3T3-
MDR1) using the calcein assay. Calcein-AM is a non-
fluorescent P-gp substrate that crosses the cell membrane
passively and, following cleavage by cytoplasmic esterases,
is converted to fluorescent calcein. As calcein is not a
substrate for P-gp, cellular fluorescence is inversely related
to the activity of P-gp [37,43].
Fig. 1A shows calcein accumulation measured by flow
cytometry in NIH3T3-MDR1 cells which express active P-
gp in the absence of inhibitor (black lines), or following
treatment with either 20 AM CsA (panel 1, red), 100 AM
h-sitosterol (panel 2, red), 100 AM cholesterol (panel 3,
red), or 90 AM methotrexate (panel 4, red). Panel 1 shows
that CsA, a known inhibitor of P-gp, increased fluores-
cence significantly (shifting the peak to the right), demon-
strating that, as expected, it does inhibit P-gp activity and
therefore increases fluorescent calcein accumulation by the
cells. CsA had no effect on the uptake of calcein-AM by
the parental NIH3T3 cell line (data not shown), confirming
that its effects are through inhibition of P-gp. The possi-
bility that CsA exhibited a toxic effect at the concentra-
tions and time period used was excluded by monitoring
propidium iodide uptake (data not shown). In contrast to
CsA, h-sitosterol, even at concentrations as high as 100
AM, had no effect on P-gp activity (panel 2, red, complete
overlay of both curves) implying that sitosterol does not
interact with P-gp. Likewise, cholesterol, structurally very
similar to sitosterol, and methotrexate, which is assumed
not to be transported by P-gp, did not affect calcein
accumulation (panels 3 and 4, complete overlay of both
curves).
In order to examine the effect of a P-gp substrate in our
experimental setup, we tested vinblastine (VBL) in a con-
centration range between 2.2 and 22 AM (Fig. 1B). As
expected, VBL interacted with P-gp and inhibited compet-
itively calcein-AM efflux in a concentration dependent
Fig. 3. Effect of sitosterol on P-gp activity in murine lymphocytes. Mesen-
teric murine lymph node cells were incubated with 0.02 AM BODIPY-taxol
for 30 min, CD4 cells separated and fluorochrome accumulation measured in
either the absence of inhibitor (thin lines), in the presence of 20 AM
cyclosporin A (CsA; panel A, thick line) or in the presence of 100 AM h-
sitosterol (panel B, thick line). Cells were analysed by flow cytometry. CsA
increased fluorescence, as expected, demonstrating inhibition of P-gp ac-
tivity, while sitosterol had no effect.
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manner (panels 1–3) resulting in significantly increased
fluorescence as illustrated by a shift of the peak to the right
and increased mean fluorescence values for the gated
population (numbers in brackets). This finding implies that
our transport assay is capable of identifying substrates for
and inhibitors of P-gp and suggests that neither sitosterol
nor cholesterol interact with P-gp.
Since the above assay only measured steady-state accu-
mulation, we also monitored the effect of sitosterol on the
rate of calcein-AM uptake by confocal microscopy. Fig. 2A
Fig. 4. Effect of sitosterol on ATPase activity. (Panel A) Relative ATPase activity in membranes isolated from P-gp-transfected Sf9 cells was measured for
verapamil (o) and h-sitosterol (.) at various concentrations. The verapamil curve has been fitted to the Michaelis–Menten equation: V=V0+(VmaxV0) S/
(S+Km). (Panel B) Kinetics of modulation of the verapamil-stimulated P-gp ATPase activity by sitosterol was determined at 0 AM (o), 1.6 AM (.), 6.3 AM
(4), 25 AM (E) and 100 AM (5) h-sitosterol. The curves have been fitted to the Michaelis–Menten equation, and the kinetic parameters obtained, Km and
Vmax are shown in the insert. Sitosterol affected neither the P-gp-associated ATPase activity (panel A) nor modulated the verapamil-activated ATPase activity of
P-gp (panel B).
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shows images of individual cells in the presence of 2.5 AM
calcein-AM before application of 100 AM h-sitosterol (left
panel), 2 min after h-sitosterol application (middle panel),
and 2 min after application of 50 AM verapamil (right
panel). Verapamil, a known inhibitor of P-gp-mediated
transport activity, increased fluorescence (calcein-AM
uptake) as expected, while in contrast, sitosterol had no
effect on P-gp activity. Quantitative analysis for several
individual cells was performed by measuring the average
fluorescence intensity from an area within the cell as a
function of time (Fig. 2B). No significant effect of h-
sitosterol on the rate of calcein-AM efflux was detected;
in contrast, and as expected, verapamil increased fluores-
cence markedly (Fig. 2A and B). Thus, even at high
concentrations, sitosterol did not affect the rate of transport
activity of P-gp.
In order to test the effects of sitosterol on P-gp activity in
a non-transfected cell system (murine lymphocytes), we
used a second fluorophore, BODIPY-taxol (Molecular
Probes), which is a specific P-gp substrate (Elliott, J., S.
Raguz, and C.F. Higgins, 2002, manuscript submitted;
[44]). Fig. 3 shows that, as expected, 20 AM CsA inhibited
BODIPY-taxol uptake (panel A), while h-sitosterol, even at
concentrations as high as 100 AM, had no effect on P-gp
activity as illustrated by the complete overlay of both curves
(panel B).
Finally, we aimed to evaluate the direct effect of h-
sitosterol at the level of the catalytic site of P-gp assuming
that its ATPase activity is directly coupled to the transport
function of the protein (reviewed in Ref. [45]). In order to
study the direct effect of h-sitosterol, ATPase activity in
membranes isolated from P-gp-transfected Sf9 cells was
tested. As Fig. 4A demonstrates, h-sitosterol did not affect
the P-gp-associated ATPase activity in the concentration
range studied. Neither was h-sitosterol able to modulate the
verapamil activated ATPase activity of P-glycoprotein (Fig.
4B), as neither the Km (the verapamil concentration at
which half-maximal ATPase activation is reached), nor the
Vmax (maximum level of verapamil-induced ATPase activ-
ity) for verapamil were affected. These results indicate that
sitosterol does not interact with the catalytic site of P-
glycoprotein.
3.2. Sitosterol does not affect Mrp1 activity
To test whether Mrp1 is able to transport sitosterol, we
used mesenteric lymph node cells from Mdr1a/b / mice
to exclude interference of P-gp in the assay. We have
previously shown that these cells from Mdr1a/b / mice
express both Mrp1 and Abcg2, but not P-gp and that the
uptake of Fluo-4-AM and calcein-AM in Mdr1a/b / mice
is mediated solely by Mrp1 (i.e. not by Abcg2) and is
specifically inhibited by MK571 (Elliott, J., S. Raguz, and
C.F. Higgins, 2002, manuscript submitted). Results are
shown for CD4-positive cells. Similar results were obtained
for CD8-positive cells.
Fig. 5A shows data for lymphocytes from Mdr1a/b /
mice incubated with calcein-AM in the presence (thick line)
or absence (thin line) of MK571. As expected, MK571
inhibited Mrp1 activity and resulted in a marked increase in
the uptake of calcein-AM (thick line). In contrast, h-sitos-
terol (Fig. 5B) did not affect Mrp1-dependent efflux of
calcein-AM even at concentrations up to 100 AM (complete
overlay of both curves). Similar results were obtained using
the fluorophore Fluo-4AM, another fluorescent substrate of
Mrp1 (data not shown). Thus sitosterol does not appear to
interact with Mrp1-mediated transport.
3.3. Sitosterol does not affect Abcg2 activity
To study Abcg2 activity, we used the fluorochrome
mitoxantrone in mesenteric lymph node cells from Mdr1a/
Fig. 5. Effect of sitosterol on Mrp1 activity. Mesenteric lymph node cells
from Mdr1a/b / mice were incubated with 0.0125 AM calcein-AM for 30
min and fluorochrome accumulation measured in CD4 cells either in the
absence of inhibitor (thin lines), or in the presence of 70 AM MK571 (Fig.
4A, thick line) or in the presence of 100 AM h-sitosterol (Fig. 4B, thick
line). Cells were analysed by flow cytometry. MK571 increased
fluorescence, as expected, demonstrating inhibition of Mrp1 activity, while
sitosterol had no effect.
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b / mice. Mitoxantrone is a specifying Abcg2 substrate
[46,47], which is not transported by Mrp1; the transport of
mitoxantrone is specifically inhibited by fumitremorgin C
([48], Elliott, J., S. Raguz and C.F. Higgins, 2002, manu-
script submitted). Fig. 6A shows that, Mdr1a/b-deficient
CD4 cells exhibited fumitremorgin C-sensitive efflux of
mitoxantrone (thick line). In contrast, sitosterol did not
affect Abcg2 transport activity (Fig. 6B).
3.4. Sitosterol does not inhibit Bsep activity
Membrane vesicles isolated from Bsep expressing Sf9
cells demonstrated marked ATP-dependent uptake of tauro-
cholate, whereas control vesicles from wild-type cells did
not (data not shown). ATP-dependent uptake of 2 AM
taurocholate by these vesicles was tested in the absence or
presence of 1–10 AM h-sitosterol (Table 1). No inhibitory
effects of sitosterol on Bsep-mediated taurocholate transport
were found, indicating that sitosterol is not a substrate for
the canalicular bile salt transporter.
4. Discussion
An increasing number of ABC transporters have been
implicated in the movement of lipids, phospholipids or other
hydrophobic compounds across cell membranes and are
attractive candidates for sitosterol transport in addition to
ABCG5 and ABCG8 which play a role in sitosterolemia
[3–5,49,50]. It as assumed, but to date has never been
functionally demonstrated, that sitosterol is definitely or
exclusively transported by ABCG5 and ABCG8. In order
to assess whether other ABC transporter candidate proteins
mediate sitosterol transport across cell membranes, we
studied their ability to transport sitosterol both in live cells
as well as in direct transport assays using Sf9 cell membrane
vesicle systems. The transporters tested were selected
because of their known role in lipid or phospholipid trans-
port and their expression in tissues involved in sterol syn-
thesis, absorption or excretion (predominantly liver and
intestine). None of the ABC transporters tested, P-gp,
Mrp1, Abcg2, and Bsep, appear to transport sitosterol.
Since cells express multiple transporters with partially
overlapping substrate specificities, it is surprising that other
ABC transporters do not compensate for the lack of sitos-
terol transport in the absence of ABCG5 and/or ABCG8 in
sitosterolemic patients. Sitosterol has a chemical structure
very similar to that of cholesterol (Fig. 7), and, given the
broad specificity of many ABC lipid transporters, it seemed
likely that sitosterol would be transported via the same
transport proteins as cholesterol. This hypothesis is sup-
ported by the finding that sitosterolemic individuals also
hyperabsorb dietary cholesterol and other sterols, including
Table 1
Effect of sitosterol on ATP-dependent uptake of taurocholate into rat Bsep
expressing Sf9 cell vesicles




Taurocholate uptake (pmol/mg protein)
Experiment 1
45 s 17.1F1.63 19.2F 1.36 17.5F 1.60
5 min 76.4F 1.78 75.1F 3.47 74.3F 2.00
2 h 45.8F 2.58 47.5F 1.20 43.9F 2.36
Experiment 2
45 s 13.9F 1.49 12.4F 1.15 15.7F 2.14
5 min 60.9F 3.67 57.6F 3.83 56.2F 7.05
2 h 25.7F 3.11 26.5F 2.76 25.3F 3.65
Membrane vesicles were isolated from Sf9 insect cells expressing rat Bsep.
Initial (45 s), intermediate (5 min) and late (2 h) ATP-dependent Bsep-
mediated taurocholate transport was measured without h-sitosterol
application (control) and after addition of 1 AM or 10 AM h-sitosterol.
Experimental data from triplicate determinations for two separate
membrane preparations are shown.
Fig. 6. Effect of sitosterol on Abcg2 activity. Mesenteric lymph node cells
from Mdr1a/b / mice were incubated with 0.5 AM mitoxantrone for 30
min and fluorochrome accumulation was measured in CD4 cells either in the
absence of inhibitor (thin lines), in the presence of 10 AM fumitremorgin C
(FTC; Fig. 5A, thick line), or in the presence of 100 AM h-sitosterol (Fig.
5B, thick line). Cells were analysed by flow cytometry. FTC increased
fluorescence, as expected, demonstrating inhibition of Abcg2 activity while
sitosterol had no effect.
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shellfish and plant sterols [3,5]. The unexpected finding
here, that none of the ABC transporters tested appear to
transport sitosterol, provides a potential explanation.
There is some indirect evidence that P-gp transports
cholesterol. For example, esterification of plasma membrane
cholesterol is inhibited after application of a variety of
compounds known to inhibit P-gp activity [9–11], and
increased expression of P-gp has been associated with
enhanced esterification of plasma membrane cholesterol
[12]. However, in these published studies, most of the
compounds tested were not necessarily specific inhibitors
of P-gp, and may have been inhibiting other transporters.
Furthermore, a recurrent problem in studying the role of P-
gp in cholesterol transport is the importance of cholesterol
as structural component of the cell membrane for the
maintenance of P-gp activity [51–53]. Thus, it has not been
possible to measure cholesterol transport by P-gp directly.
The demonstration here that sitosterol in not a substrate
for P-gp has potential implications for cholesterol uptake.
Sitosterol is chemically very similar to cholesterol, and thus
our findings strongly suggest that cholesterol is unlikely to
be a substrate for P-gp or any of the other ABC transporters
tested. It is, of course, possible that the additional ethyl
group at carbon atom 24 (Fig. 7, arrow), the only structural
difference between sitosterol and cholesterol, may generate
specificity of the compound. However, P-gp has few clear
structural determinants to its specificity, so this seems
unlikely. This was also confirmed by our experiments where
cholesterol, as sitosterol, failed to show an inhibitory effect
upon P-gp transport activity. It therefore appears that most
ABC transporters, which otherwise have broad specificity
for hydrophobic molecules, may have acquired specificity to
exclude sterols such as cholesterol, presumably because the
abundant cholesterol in the cell membrane would otherwise
compete for transport. Where there is a need for sterol
transport, specific ABC transporters have evolved to accom-
modate this biological requirement.
In summary, the four ABC transporters investigated in
this study are unlikely to play a significant role in sitosterol
transport. This has implications for the specificity and the
biological roles of these ABC transporters, suggesting that
they are unlikely to be involved in cholesterol transport.
Additionally, with respect to the pathology of sitosterolemia
the data suggest that specialization has occurred such that
specific ABC transporters have adapted to handle sitosterol
and related sterols distinct from the relatively broad specif-
icity of other ABC transporters.
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